BioMarin Pharmaceutical (BMRN) secures an Ad Com vote in favor of approval of Vimizim for the treatment of Morquio A syndrome. 19 panel members voted in favor of the drug's use in all MPS IVA patients, 1 for approval in a subgroup, and 1 for not recommending approval.
A PDUFA action date of Feb. 28 has been assigned.
Shares are up 3.1% AH after trading resumed from the earlier halt.
Previous: FDA says BioMarin drug results in "modest" improvements